FTY720 inhibits proliferation and epithelialmesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Lu, Zhaoyang ^a   Wang, Jiabei ^a   Zheng, Tongsen ^a   Liang, Yingjian ^a   Yin, Dalong ^a   Song, Ruipeng ^a   Pei, Tiemin ^a   Pan, Shangha ^a   Jiang, Hongchi ^a   Liu, Lianxin ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Cholangiocarcinoma; FTY720; STAT3

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN D1; CYCLIN E; FINGOLIMOD; NERVE CELL ADHESION MOLECULE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BCL XL; STAT3 PROTEIN; SURVIVIN; TRANSCRIPTION FACTOR TWIST; VASCULOTROPIN; VIMENTIN; CASPASE; CELL CYCLE PROTEIN; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CHOLANGIOCARCINOMA CELL LINE; CONCENTRATION RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; G1 PHASE CELL CYCLE CHECKPOINT; HUCCT1 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN DEPHOSPHORYLATION; QBC939 CELL LINE; SIGNAL TRANSDUCTION; TFK 1 CELL LINE; TUMOR INVASION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; INTRAHEPATIC BILE DUCT; METABOLISM; METASTASIS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CASPASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASM METASTASIS; PHOSPHORYLATION; PROPYLENE GLYCOLS; SIGNAL TRANSDUCTION; SPHINGOSINE; STAT3 TRANSCRIPTION FACTOR; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929940184     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-783     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
2. Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, Wiangnon S, Sripa B, Hong ST: Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci 2010, 101(3):579-585.
3. Eslick GD: Epidemiology of gallbladder cancer. Gastroenterol Clin North Am 2010, 39(2):307-330. ix.
4. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD: Cholangiocarcinoma. Lancet 2005, 366(9493):1303-1314.
5. Sirica AE: Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005, 41(1):5-15.
6. Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9(11):798-809.
7. Yu H, Kortylewski M, Pardoll D: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007, 7(1):41-51.
8. Cheng F, Wang HW, Cuenca A, Huang M, Ghansah T, Brayer J, Kerr WG, Takeda K, Akira S, Schoenberger SP, Yu H, Jove R, Sotomayor EM: A critical role for Stat3 signaling in immune tolerance. Immunity 2003, 19(3):425-436.
9. Kasprzycka M, Marzec M, Liu X, Zhang Q, Wasik MA: Nucleophosmin/ anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci U S A 2006, 103(26):9964-9969.
10. Benekli M, Baer MR, Baumann H, Wetzler M: Signal transducer and activator of transcription proteins in leukemias. Blood 2003, 101(8):2940-2954.
11. Buettner R, Mora LB, Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002, 8(4):945-954.
12. Levy DE, Lee CK: What does Stat3 do? J Clin Invest 2002, 109(9):1143-1148.
13. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, Dalton WS, Jove R: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10(1):105-115.
14. Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, Gores GJ: Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005, 42(6):1329-1338.
15. Zheng T, Hong X, Wang J, Pei T, Liang Y, Yin D, Song R, Song X, Lu Z, Qi S, Liu J, Sun B, Xie C, Pan S, Li Y, Luo X, Li S, Fang X, Bhatta N, Jiang H, Liu L: Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma. Hepatology 2014, 59(3):935-946.
16. Tedesco-Silva H, Mourad G, Kahan BD, Boira JG, Weimar W, Mulgaonkar S, Nashan B, Madsen S, Charpentier B, Pellet P, Vanrenterghem Y: FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2004, 77(12):1826-1833.
17. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006, 355(11):1124-1140.
18. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR: The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002, 277(24):21453-21457.
19. Graler MH, Goetzl EJ: The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004, 18(3):551-553.
20. Azuma H, Takahara S, Ichimaru N, Wang JD, Itoh Y, Otsuki Y, Morimoto J, Fukui R, Hoshiga M, Ishihara T, Nonomura N, Suzuki S, Okuyama A, Katsuoka Y: Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res 2002, 62(5):1410-1419.
21. Azuma H, Takahara S, Horie S, Muto S, Otsuki Y, Katsuoka Y: Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol 2003, 169(6):2372-2377.
22. Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T: A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol 2003, 138(7):1303-1312.
23. Whitnall M, Howard J, Ponka P, Richardson DR: A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A 2006, 103(40):14901-14906.
24. Balsari A, Tortoreto M, Besusso D, Petrangolini G, Sfondrini L, Maggi R, Menard S, Pratesi G: Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur J Cancer 2004, 40(8):1275-1281.
25. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S: An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 1999, 5(2):221-225.
26. Dunn LL, Sekyere EO, Suryo Rahmanto Y, Richardson DR: The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis. Carcinogenesis 2006, 27(11):2157-2169.
27. Gao J, Richardson DR: The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood 2001, 98(3):842-850.
28. Chua CW, Lee DT, Ling MT, Zhou C, Man K, Ho J, Chan FL, Wang X, Wong YC: FTY720, a fungus metabolite, inhibits in vivo growth of androgenindependent prostate cancer. Int J Cancer 2005, 117(6):1039-1048.
29. Tannapfel A, Benicke M, Katalinic A, Uhlmann D, Kockerling F, Hauss J, Wittekind C: Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000, 47(5):721-727.
30. Thongprasert S: The role of chemotherapy in cholangiocarcinoma. Ann Oncol 2005, 16(Suppl 2):ii93-ii96.
31. Briggs CD, Neal CP, Mann CD, Steward WP, Manson MM, Berry DP: Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur J Cancer 2009, 45(1):33-47.
32. Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, Lehman A, Perrotti D, Chen CS, Dalton JT, Muthusamy N, Byrd JC: FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 2008, 111(1):275-284.
33. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003, 374(Pt 1):1-20.
34. Nielsen M, Kaltoft K, Nordahl M, Ropke C, Geisler C, Mustelin T, Dobson P, Svejgaard A, Odum N: Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci U S A 1997, 94(13):6764-6769.
35. Rath KS, Naidu SK, Lata P, Bid HK, Rivera BK, McCann GA, Tierney BJ, Elnaggar AC, Bravo V, Leone G, Houghton P, Hideg K, Kuppusamy P, Cohn DE, Selvendiran K: HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer. Cancer Res 2014, 74(8):2316-2327.
36. Chen H, Yang Z, Ding C, Xiong A, Wild C, Wang L, Ye N, Cai G, Flores RM, Ding Y, Shen Q, Zhou J: Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3). Eur J Med Chem 2014, 82:195-203.
37. Eiring AM, Page BD, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Colaguori R, Moriggl R, Wilson DJ, Baron R, O'Hare T, Gunning PT, Deininger MW: Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia 2014. [Epub ahead of print].
38. Gu L, Talati P, Vogiatzi P, Romero-Weaver AL, Abdulghani J, Liao Z, Leiby B, Hoang DT, Mirtti T, Alanen K, Zinda M, Huszar D, Nevalainen MT: Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther 2014, 13(5):1246-1258.
39. Hung JH, Lu YS, Wang YC, Ma YH, Wang DS, Kulp SK, Muthusamy N, Byrd JC, Cheng AL, Chen CS: FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Res 2008, 68(4):1204-1212.
40. Liao A, Broeg K, Fox T, Tan SF, Watters R, Shah MV, Zhang LQ, Li Y, Ryland L, Yang J, Aliaga C, Dewey A, Rogers A, Loughran K, Hirsch L, Jarbadan NR, Baab KT, Liao J, Wang HG, Kester M, Desai D, Amin S, Loughran TP Jr, Liu X: Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood 2011, 118(10):2793-2800.
41. Li CX, Shao Y, Ng KT, Liu XB, Ling CC, Ma YY, Geng W, Fan ST, Lo CM, Man K: FTY720 suppresses liver tumor metastasis by reducing the population of circulating endothelial progenitor cells. PLoS One 2012, 7(2):e32380.
42. Chua CW, Chiu YT, Yuen HF, Chan KW, Man K, Wang X, Ling MT, Wong YC: Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Clin Cancer Res 2009, 15(13):4322-4335.
43. Okada K, Shimizu Y, Nambu S, Higuchi K, Watanabe A: Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol 1994, 9(5):462-467.
44. Park J, Tadlock L, Gores GJ, Patel T: Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 1999, 30(5):1128-1133.
45. Yu H, Jove R: The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004, 4(2):97-105.
46. Balanis N, Wendt MK, Schiemann BJ, Wang Z, Schiemann WP, Carlin CR: Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. J Biol Chem 2013, 288(25):17954-17967.